Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar
Tue, 24/04/2018 - 09:49
0 min
Español
NoticiasWeb_English_0.png
Download related document
Select rating
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 1/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 2/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 3/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 4/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 5/5
No votes yet
Related
ROVI reports operating revenue growth of 12% and net profit growth of 53%
Today, Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specialising and engaging in the...
5 min
24/11/2020
First nine months 2020 Results Press Release
0 min
05/11/2020
First nine months 2020 results presentation
0 min
05/11/2020
See More
Email
Facebook
Twitter
LinkedIn
NoticiasWeb_English_0.png